Sara Jane Ward, PhD, Assistant Professor of Pharmacology at the Lewis Katz School of Medicine at Temple University, participated in a Q&A with Philadelphia magazine about a recent study that was published online in the British Journal of Pharmacology. The work by Dr. Ward, who is the senior investigator, and colleagues suggests a novel CBD analog known as KLS-13019 may help overcome the low bioavailability of cannabidiol, or CBD. Studies have shown CBD reduces pain sensation in animals, but its ability to do so in humans is limited by its low bioavailability, or the extent to which the drug successfully reaches its site of action.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH